NEW YORK--The Cancer Research Institute and Cancer Care, Inc. have announced The Melanoma Initiative, a program to support public awareness of melanoma, resources for melanoma patients, and clinical research. The Initiative is funded by an unrestricted educational grant from Schering-Plough Corporation.
NEW YORK--The Cancer Research Institute and Cancer Care, Inc. have announcedThe Melanoma Initiative, a program to support public awareness of melanoma,resources for melanoma patients, and clinical research. The Initiativeis funded by an unrestricted educational grant from Schering-Plough Corporation.
Under the auspices of the Initiative's research component, the CancerResearch Institute will establish a program to support phase I/II clinicaltrials aimed at testing novel immunotherapies for melanoma. Close to $1million in grants will be awarded from 1997 to 1999.
Patient outreach services will include counseling and practical assistance;telephone support groups and educational seminars; a "buddy"program where melanoma patients can talk with other patients; guidanceon medical services; a referral program identifying local community resources;and guidance on how to obtain home care, transportation, child care, andfinancial assistance.
These services will be available through Cancer Care's offices, itsNational Counseling Line, 1-800-813-HOPE, and its Web Site (http://www.cancercareinc.org).The centerpiece of the educational outreach component is the creation offour advertisements for People magazine.
Tebentafusp Continues to Demonstrate Benefit in Metastatic Uveal Melanoma
January 4th 2024Results from a long-term analysis of the phase 3 IMCgp100-202 trial indicate that tebentafusp results in better disease control and long-lasting responses in those with HLA-A*02:01–positive, previously untreated metastatic uveal melanoma.